(R)-4,5,6,7-Tetrahydro-Benzothiazole-2,6-Diamine

The (R)-configured 4,5,6,7-tetrahydrobenzothiazole-2,6-diamine, systematically identified as (R)-2,6-diamino-4,5,6,7-tetrahydrobenzothiazole, functions as a high-purity chiral C2-symmetric diamine building block within early-stage pharmaceutical synthesis and enantioselective ligand construction. Typical commercial material is supplied as a white to off-white crystalline free base with a molecular weight of 169.25 g·mol⁻¹ and a melting point exceeding 185 °C (decomposition). Chemical purity, determined by reversed-phase HPLC (C18, 250 × 4.6 mm, 5 µm; phosphate buffer pH 3.0/acetonitrile gradient) with UV detection at 254 nm, consistently exceeds 98.5% (area-%). Enantiomeric excess is controlled to a specification limit of ≥99.0% ee, measured on a derivatized amylose-based chiral stationary phase (Chiralpak IA, 250 × 4.6 mm, 5 µm) under isocratic n-hexane/ethanol/0.1% diethylamine conditions, referencing the (S)-antipode as the principal chiral impurity. Residual solvent levels are validated against ICH Q3C guidelines, with typical lot values for ethanol and n-heptane each below 500 ppm. The diamine is inherently hygroscopic; water content by Karl Fischer titration is regularly reported below 0.3% after drying in vacuo (40 °C, 16 h). The product is packaged under argon in amber glass ampoules of 1 g, 5 g, or 25 g net fill to suppress oxidative discoloration and moisture uptake.

When Manufacturing Enantiopure Pramipexole Hydrochloride: The Role of (R)-Diamine

Pramipexole hydrochloride monohydrate, an S-enantiomer dopamine D₂/D₃ agonist, is assembled from (S)-2-amino-6-(n-propylamino)-4,5,6,7-tetrahydrobenzothiazole. In convergent synthetic routes, the (R)-diamine scaffold serves as a chiral starting material that undergoes subsequent N-6 propylation with retention or inversion of configuration, depending on the reductive amination strategy. A representative two-step sequence first protects the C-2 primary amine as a Boc-carbamate (Boc₂O, triethylamine, THF, 0–5 °C, 2 h) to yield (R)-2-(tert-butoxycarbonylamino)-6-amino-4,5,6,7-tetrahydrobenzothiazole with >95% isolated yield. Propionaldehyde is then introduced in the presence of sodium triacetoxyborohydride in 1,2-dichloroethane at 25 °C under a nitrogen atmosphere. The crude product, after acidic Boc deprotection and hydrochloride salt formation, yields the (S)- or (R)-configured pramipexole free base depending on the chiral integrity of the starting diamine: processing of the (R)-diamine under reductive amination conditions that preserve the stereogenic centre at C-6 furnishes (R)-pramipexole, the pharmacologically less active enantiomer, with an enantiomeric ratio typically exceeding 99.5:0.5 when monitored mid-process by chiral HPLC. Conversely, intentional epimerisation through a ketimine intermediate allows access to the therapeutically desired (S)-pramipexole from the same (R)-diamine feedstock, a strategy occasionally preferred to avoid the higher cost of (S)-diamine procurement. Omission of rigorous moisture control during the reductive amination step can depress yield to <70% due to aldehyde hydration and borohydride consumption, a failure mode documented in pilot-scale jacketed reactors (stainless steel 316L, 50 L working volume) equipped with anhydrous solvent loops.

Chiral HPLC Method Performance Data

Enantiomeric purity of both the diamine intermediate and downstream pramipexole intermediates is quantified using a validated normal-phase HPLC system. The method employs a Chiralpak IA column (250 × 4.6 mm i.d., 5 µm particle size) operated at 30 °C with a mobile phase mixture of n-hexane, ethanol, and diethylamine in a volume ratio of 80:20:0.1 at a flow rate of 1.0 mL·min⁻¹. Injection volume is 10 µL of a 1.0 mg·mL⁻¹ sample solution in ethanol, and detection is set at 262 nm. Under these conditions, the (R)-diamine elutes at approximately 9.2 min, while the (S)-enantiomer is retained longer with a resolution factor R_s routinely greater than 2.5. System suitability requirements include a tailing factor below 1.8 and a relative standard deviation of peak area <1.0% across six replicate injections of a 0.1 mg·mL⁻¹ standard. The method’s limit of quantitation for the undesired enantiomer is established at 0.05% with respect to the main peak, consistent with ICH Q2(R1) guidelines for impurity testing. Calibration linearity across 0.05% to 5.0% of the minor enantiomer yields correlation coefficients >0.999. No interference from process-related achiral impurities at the specified detection wavelength is observed. This analytical framework is transferable to LC–MS platforms for in-process control when coupled to single quadrupole mass detectors operating in positive electrospray ionisation mode. Storage of the (R)-diamine in unopened, argon-flushed glassware at 2–8 °C is validated for 24 months under ICH Q1A(R2) long-term conditions. After initial opening, the free base must be handled inside a glovebox or under a positive pressure of dry nitrogen; exposure to ambient air at relative humidity above 60% for more than 30 minutes leads to clumping and a detectable drop in HPLC purity to <97% due to carbamate formation from atmospheric carbon dioxide and colour body generation. For dispensing, a stainless steel spatula pre-cooled to −20 °C minimises electrostatic adhesion. The compound is incompatible with strong oxidisers, acid anhydrides, and acyl chlorides; contact with methylene chloride under basic conditions can generate trace N-chloromethyl derivatives detectable by LC–MS as the [M+H]⁺ adduct at m/z 218.1. When incorporated into palladium-catalysed cross-coupling sequences, pre-coordination of the free amine in toluene at 60 °C for 30 min prior to addition of the metal source is recommended to avoid catalyst poisoning by the basic thiazole nitrogen.

Comparative enantiomeric purity and physicochemical constants of the (R)-enantiomer, (S)-enantiomer, and racemic (±)-2,6-diamino-4,5,6,7-tetrahydrobenzothiazole

Parameter	(R)-Enantiomer	(S)-Enantiomer	Racemate
Specific optical rotation [α]D20 (c 1.0, MeOH)	−29.5° to −31.0°	+29.0° to +30.5°	0° ± 0.5°
Enantiomeric excess (chiral HPLC)	≥99.0%	≥99.0%	<1%
Melting range (DSC, onset)	192–195 °C (dec.)	191–194 °C (dec.)	178–182 °C (dec.)
Typical water content (KF)	<0.3%	<0.3%	<0.5%
Residue on ignition	<0.1%	<0.1%	<0.2%

What Limits the Utility of Racemic 2,6-Diamino-Tetrahydrobenzothiazole?

Racemic 2,6-diamino-4,5,6,7-tetrahydrobenzothiazole, although available at lower cost, imposes intrinsic process efficiency penalties whenever downstream chiral resolution is required. Classical diastereomeric salt formation with chiral acids such as L-(+)-tartaric acid or dibenzoyl-D-tartaric acid in methanol/water mixtures yields a single crystallisation recovery that rarely exceeds 35% theoretical based on one enantiomer, with mother liquor enrichment in the antipode demanding multiple recrystallisation cycles to approach 99% ee. The copious solvent volumes—often 15–20 L per kilogram of racemate—and the generation of mixed-salt waste streams create a processing bottleneck when scaling beyond laboratory batches. Direct use of the racemate in enantioselective synthesis (e.g., as a substrate for lipase-mediated kinetic resolution) has been examined with Candida antarctica lipase B and vinyl acetate in tert-butyl methyl ether, but e-values (enantiomeric ratio) plateau at ~45, insufficient to yield product meeting ICH Q3A purity thresholds without extensive chromatographic polishing. Consequently, single-enantiomer (R)-diamine sourced with defined stereochemical purity bypasses this resolution step entirely, eliminating the solvent burden and enabling linear synthesis campaigns that are directly transferrable to current Good Manufacturing Practice (cGMP) intermediate production. Incorporation of the (R)-diamine into bidentate phosphoramidite or sulfonamide ligand frameworks illustrates its divergence from the corresponding (S)-enantiomer in asymmetric induction. When the diamine is reacted with (S)-BINOL-derived chlorophosphite in THF at −78 °C, the resulting phosphoramidite ligand furnishes opposite enantiofacial selectivity in rhodium-catalysed hydrogenation of methyl (Z)-2-acetamidocinnamate compared to the ligand derived from the (S)-diamine. Under 5 bar H₂ pressure at 25 °C in dichloromethane, the (R)-derived ligand system consistently delivers the S-amino acid product with 93–96% ee, while the (S)-derived analogue gives the R product with 91–94% ee, as quantified by chiral GC after derivatisation. This stereodivergent access is leveraged in medicinal chemistry programs where both enantiomers of a target are required for pharmacological profiling. The diamine’s C-2 amine group typically remains unprotected during ligand formation, enabling late-stage metal coordination, whereas the C-6 amine undergoes sulfonylation with p-toluenesulfonyl chloride (pyridine, 0–5 °C, 12 h) to introduce a crystalline handle that simplifies purification. The (R)-enantiomer’s distinct crystal habit (fine needles from ethanol/water) relative to the (S)-form (prisms) provides a simple morphological identification aid after recrystallisation, though formal authentication always relies on chiral HPLC. Pilot-scale experience with this diamine in a 100-L glass-lined reactor employed for an active pharmaceutical ingredient (API) intermediate highlighted a narrow thermal window during solvent swap from isopropanol to ethyl acetate: distillation at jacket temperatures exceeding 60 °C triggered partial racemisation, raising the (S)-impurity from 0.3% to 1.8% within 2 h, as traced by in-process sampling. Implementation of vacuum distillation at 50 mbar with a jacket setpoint of 45 °C preserved enantiopurity within specification, demonstrating that the processing window for this intermediate does not extend beyond 55 °C for prolonged bulk exposure. Such thermal sensitivity is absent in the racemate and less pronounced in the (S)-enantiomer under identical conditions, a discrepancy attributed to differential interconversion barriers in the crystalline phase. The (R)-diamine’s forced degradation profile under ICH Q1B photostability conditions (ICH Option 2, 1.2 million lux·h visible and 200 W·h·m⁻² UV) reveals 2.1% total degradation products at 254 nm, qualifying it as photostable for handling in amber glass.

Standard analytical release criteria for (R)-4,5,6,7-tetrahydrobenzothiazole-2,6-diamine and applicable guideline cross-references

Test attribute	Methodology	Acceptance limit	Reference standard
Appearance	Visual inspection	White to off-white crystalline powder	—
Identification (IR)	ATR-FTIR, 4000–400 cm⁻¹	Matches reference spectrum	Ph. Eur. 2.2.24
Chemical purity	RP-HPLC (C18, 250 mm, 5 µm), gradient, UV 254 nm	≥98.5% area	Ph. Eur. 2.2.29
Enantiomeric purity	Chiral NP-HPLC (amylose tris(3,5-dimethylphenylcarbamate)), isocratic, UV 262 nm	(S)-isomer ≤1.0%, typically ≤0.5%	ICH Q2(R1)
Water content	Karl Fischer coulometric titration	≤0.5%	Ph. Eur. 2.5.12
Heavy metals	ICP-MS	Pb, Cd, Hg, As each <5 ppm	ICH Q3D (oral)
Residual solvents	Headspace GC-FID	Ethanol <500 ppm, n-heptane <200 ppm	ICH Q3C
Assay (as free base)	Non-aqueous titration (0.1 M HClO₄ in glacial acetic acid)	98.0–102.0%	Ph. Eur. 2.2.20

A separate application niche exploits the (R)-diamine’s bis-nucleophilic character for the construction of macrocyclic receptors. Condensation with 2,6-pyridinedicarbonyl dichloride in high-dilution THF (catalyst: triethylamine, 0 –5 °C, 24 h) yields a chiral tetraamide cryptand capable of selective lanthanide binding. The (R)-enantiomer-derived cryptand exhibits a binding constant (log K) for Eu³⁺ in acetonitrile/water (95:5 v/v) of 5.8 ± 0.2, while the (S)-enantiomer-derived analogue yields log K 6.0 ± 0.1, highlighting a subtle host-guest chiral discrimination that is inverted when the metal is switched to Tb³⁺. These findings underscore the absolute configuration-dependence of molecular recognition and confirm that when the synthetic objective extends beyond bulk pharmacopoeial intermediate supply, access to the (R)-diamine as a distinct entity—rather than the racemate—is mandatory for reproducing structure-activity correlations.